Drug news
FDA accepts re filing of NDA for Macrilen (macimorelin) to treat growth hormone deficiency.- Aeterna Zentaris Inc.
Aeterna Zentaris Inc. announced that it has been notified by the FDA, that the Company�s New Drug Application seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults has been accepted as a complete response to the FDA�s November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017.